All AbMole products are for research use only, cannot be used for human consumption.
Panitumumab is a fully human IgG2 monoclonal antibody specific to the epidermal growth factor receptor (EGFR). Panitumumab works by binding to the extracellular domain of the EGFR preventing its activation. This results in halting of the cascade of intracellular signals dependent on this receptor. The pharmacokinetics (PK) of panitumumab shows the so-called target-mediated disposition behavior.
ACS Appl Mater Interfaces. 2023 Jan 26.
Protein Release by Controlled Desorption from Transiently Cationic Nanoparticles
Panitumumab purchased from AbMole
Patent. US2023364025A1 2023 Nov 16.
Patent. US2023364025A1
Panitumumab purchased from AbMole
Patent. CA3158870A1 2023 Nov 12.
Patent. CA3158870A1
Panitumumab purchased from AbMole
| Molecular Weight | 144321.76 |
| Formula | C6398H9878N1694O2016S48 |
| CAS Number | 339177-26-3 |
| Storage | -80°C for long term |
| Related EGFR/HER2 Products |
|---|
| Sevabertinib
Sevabertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antitumor activity. |
| BPIQ-I
BPIQ-I (PD 159121) is a potent and ATP-competitive EGFR tyrosine kinase inhibitor.. |
| HKI-357
HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 with IC50s of 34 nM and 33 nM, respectively. |
| SJF-1528
SJF-1528 is a potent EGFR PROTAC degrader with DC50 values of 39.2 nM and 736.2 nM for wild-type EGFR in OVCAR8 cells and Exon 20 Ins mutated EGFR in HeLa cells. |
| CH7233163
CH7233163 is a noncovalent ATP-competitive inhibitor for EGFR-Del19/T790M/C797S. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
